



02/02/05

1fw

Express Mail No. EV452774364US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Perez-Soler et al.

Confirmation No: 8956

Serial No.: 10/750,382

Group Art Unit: 1614

Filed: December 30, 2003

Examiner: To be assigned

For: **DELIVERY AND ACTIVATION
THROUGH LIPOSOME INCORPORATION
OF DIAMINOCYCLOHEXANE
PLATINUM(II) COMPLEXES**

Attorney Docket No.: 8449-320-999

INFORMATION DISCLOSURE STATEMENT

COMMISSIONER FOR PATENTS
P.O. BOX 1450
Alexandria, Virginia 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R.

§1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references A01-A26, B01-B10 and C01-C35 listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant."

The above-identified application is a continuation of U.S. patent application Serial No. 09/168,799, filed October 8, 1998, now Patent No. 6,696,079, issued February 24, 2004; which is a division of U.S. patent application Serial No. 08/764,095, filed on December 6, 1996, now Patent No. 5,843,475, issued December 1, 1998. References A01-A25, B01-B10 and C01-C35 are of record in the 09/168,799 and/or 08/764,095

applications. Therefore, pursuant to 37 C.F.R. §1.98(d), copies of these references are not submitted herewith. Furthermore, copies of references A26-A28, being U.S. patents, are not submitted herewith pursuant to 37 C.F.R. §1.98(a)(2)(ii).

It is respectfully requested that these references be made of record in the application.

This Information Disclosure Statement is being submitted before the mailing date of a first Office Action on the merits; therefore, pursuant to 37 C.F.R. § 1.97(b)(3), no fee is believed due. However, should the Patent and Trademark Office determine otherwise, please charge any required fee to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: January 31, 2005

 32,605
Adriane M. Antler (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
Tel.: (212) 326-3939

Enclosure

<p style="text-align: center;">LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small></p> <p style="text-align: center;">JAN 3 1 2005</p> 		ATTY DOCKET NO. 8449-320-999	APPLICATION NO. 10/750,382
		APPLICANT Perez-Soler et al.	
		FILING DATE December 30, 2003	GROUP 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A01	3,904,663	9/75	Tobe et al.			
A02	4,169,846	10/2/79	Kidani et al.			
A03	4,200,583	4/29/80	Kidani et al.			
A04	4,203,912	5/20/80	Hydes et al.			
A05	4,230,631	10/28/80	Hydes et al.			
A06	4,255,347	3/10/81	Kidani et al.			
A07	4,256,652	3/17/81	Kidani et al.			
A08	4,431,666	2/14/84	Bulten et al.			
A09	4,466,924	8/21/84	Verbeek et al.			
A10	4,661,516	4/28/87	Brown et al.			
A11	4,758,588	7/19/88	Brown et al.			
A12	4,760,155	7/26/88	Heffernan et al.			
A13	4,760,157	7/26/88	Child et al.			
A14	4,845,124	7/4/89	Kidani et al.			
A15	4,861,905	8/29/89	Nowatari et al.			
A16	4,946,954	8/7/90	Talebian et al.			
A17	4,956,459	9/11/90	Talebian et al.			
A18	5,011,959	4/30/91	Khokhar et al.			
A19	5,041,578	8/20/91	Khokhar			
A20	5,041,581	8/20/91	Khokhar et al.			
A21	5,117,022	5/26/92	Khokhar et al.			
A22	5,178,876	2/12/93	Khokhar et al.			
A23	5,186,940	2/16/93	Khokhar et al.			
A24	5,384,127	1/24/95	Perez-Soler et al.			
A25	5,422,364	6/6/95	Nicolau			
A26	5,843,475	12/1/98	Perez-Soler et al.			
A27	6,613,799	9/2/03	Maeda et al.			
A28	6,696,079	2/24/04	Perez-Soler et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
B01	EP 0113508	7/18/84	EP				
B02	EP 0130482	1/9/95	EP				
B03	EP 0136012	4/3/85	EP				

	B04	EP 0147926	7/10/85	EP				
	B05	EP 0193936	5/6/89	EP				
	B06	EP 0237450	9/16/87	EP				
	B07	EP 0356332	2/28/90	EP				
	B08	WO 87/02364	4/23/87	PCT				
	B09	WO 88/03925	6/2/88	PCT				
	B10	WO 90/02131	3/8/90	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Connors, T.A. et al, "New Platinum Complexes with Anti-Tumor Activity"Chem.-Biol. Interactions, 5:415-424 (1972).
C02	Craciunescu, D.G. et al, "On the preparation, antitumour and cytotoxic evaluation of some new analogues of the cis-dichloro (1,2-diamino-cyclohexane) platinum (II) complex", Eur. J. Med. Chem.-Chem. Ther., 19:353-357 (1984).
C03	Deliconstantinos, G. et al, "Incorporation of Cis-Dichlorobiscyclopentylamineplatinum (II) into Liposomes Enhances its Uptake by Adj/PC6A Tumours Implanted Subcutaneously into Mice", Abstract from Biochem. Soc. Trans., 5(5):1326-1328 (1977).
C04	Freise, J. et al, "Pharmacokinetics of Liposome Encapsulated Cisplatin in Rats", Archies Internationales de Pharmacodynamie et de Therapie, 258(2):180-192 (Aug. 1982).
C05	Han et al., 1996, "Intraliposomal conversion of lipophilic cis-bis-carboxylato-trans-R,R-1,2-diaminocyclohexane-platinum (II) complexes into cis-bis-dichloro-trans-R,R-1,2-diaminocyclohexane-platinum (II)", Cancer Chemother. Pharmacol. 39:17-24.
C06	Han et al., Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Cancer Res. 53:4913-19, 1993.
C07	Han et al., Intraliposomal conversion of lipophilic 1,2-DACH-bisalkyl-platinum(II) complexes into DACH-Pt-Cl.sub.2 (II). Proceed AACR 37:2740 p. 401, 1996.
C08	Han et al., Liposomal-platinum (II) compounds (L-Pt): optimization of formulation parameters. Proceed AACR 35:2482 p. 416., 1994.
C09	Hollis et al., cis-diamineplatinum (II) complexes containing phosphono carboxylate ligands as antitumor agents. J Med Chem. 33:105-11, 1990.
C10	Ismail et al., .sup.195 Pt- and .sup.15 N-NMR studies of antitumor complexes. ACS Symposium Series, 209:171-190, 1983.
C11	Kaledin, V. et al, "Intralymphatic Administration of Liposome-Encapsulated Drugs to Mice: Possibility for Suppression of the Growth of Tumor Metastases in the Lymph Nodes", Jncl. 66(5):881-886 (May 1981).
C12	Khokhar et al., Chemical and biological studies on a series of lipid-soluble (trans-(R,R)- and -S,S)-1,2-Diaminocyclohexane) Platinum(II) Complexs Incorporated in Liposomes. J. Med. Chem. 34:325-329, 1991.
C13	Khokhar et al., Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes. Cancer Chemother Pharmacol. 23:219-24, 1989.
C14	Khokhar et al., Toxicity and efficacy studies on a series of lipid-soluble dineodecanoato(trans-R,R- and trans-S,S-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes. Anticancer Drugs. 3:95-100, 1992.
C15	Khokhar, A.R. et al, "The Synthesis and Antitumor Properties of a Series of Water Soluble carboxylato-(1,2-diaminocyclohexane) Platinum(II) Complexes", Inorganica chimica Acta, 108(1):63-66 (Sep. 1985).
C16	Li et al., Improved antitumor activity of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) entrapped in long-circulating liposomes. Oncology Res. 7:611-17, 1995.
C17	Mori et al., In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Cancer Chemother Pharmacol. 37:435-44, 1996.
C18	Perez-Soler et al., Clinical development of Liposomal Platinum. J Lip Res. 1:437-449, 1990.
C19	Perez-Soler et al., Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles. Cancer Res. 48:4509-12, 1988.

	C20	Perez-Soler et al., Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Cancer Res. 52:6341-47, 1992.
	C21	Perez-Soler et al., Lipophilic cisplatin analogues entrapped in liposomes: role of chemical structure and liposome composition. Proceed AACR 32:2425 p.408, 1991
	C22	Perez-Soler et al., Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylato leaving groups. cancer Chemother Pharmacol. 33:378-84, 1994.
	C23	Perez-Soler et al., Lipophilic platinum compounds entrapped in liposomes: enhanced intraliposomal stability and preserved antitumor activity by using analogs with linear aliphatic leaving groups. Proceed AACR. 34:2182 p. 366, 1993.
	C24	Perez-Soler et al., Liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP): effect of lipid composition on biological activity. Proceed AACR. 31:2542 p. 428, 1990.
	C25	Perez-Soler, et al, "Phase I Clinical and Pharmacological Study of Liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane Platinum(II)", Cancer Research, 50(14):4254-4259 (Jul. 1990).
	C26	Qu et al., Effect of diamine linker on the chemistry of Bis(Platinum) complexes. A comparison of the Aqueous solution behavior of 1,4-butanediamine and 2,5-dimethyl-2,5-Hexanediamine Complexes. J. Inorganic Biochem. 40:255-264., 1990
	C27	Qu et al., Effect of diamine linker on the chemistry of Bis(Platinum) complexes. A comparison of the Aqueous solution behavior of 1,4-butanediamine and 2.5-dimethyl-2,5-Hexanediamine Complexes. J. Inorganic Biochem. 40:255-264., 1990.
	C28	Qu et al., Interaction of bis(platinum) complexes with the mononucleotide 5'-guanosine monophosphate. Effect of diamine linker and the nature of the bis(platinum) complex of product formation. J. Am. Chem. Soc. 113:4851-4857, 1991.
	C29	Ridgway, H.J. et al, "Analogs of Sulfato 1,2-Diaminocyclohexane Platinum(II) I Modifications in Leaving Ligand", Wadley Medical Bulletin, 7(1):220,229 (1977).
	C30	Schwartz, P. et al, "Preparation and Antitumor Evaluation of Water-Soluble Derivatives of Dichloro(1,2-diaminocyclohexane)platinum(II)", Cancer Treatment Reports, 61(8):1519-1525 (Nov., 1977).
	C31	Slavin et al., Phosphonato complexes of platinum(II): kinetics of formation and phosphorus-31 NMR characterization studies. J Inorg Biochem. 40: 339-47, 1990.
	C32	Sur et al, "Effect of liposomal encapsulation of cis-platinum diaminodichloride in the treatment of Ehrlich ascites carcinoma", Oncology, 40(5):372-376 (1983).
	C33	Vollano, J.F. et al, "Comparative Antitumor Studies on Platinum(II) and Platinum(IV) Cmplexes Containing 1,2-Diaminocyclohexane", J. Med. Chem., 30:716-719 (1987).
	C34	Yatvin, M.B. et al, "Selective Delivery by Hyperthermia of Liposome Encapsulated Cis Dichlorodiamine Platinum (II) and Tumor Growth Delay", Abstract from Proc. Am. Assoc. Cancer Res., 21:281 (1980).
	C35	Yatvin, M.B. et al, "Selective Delivery of liposome-associated cis-dichlorodiamineplatinum (II) by heat and its influence on tumor drug uptake and growth", Cancer Research, 41(5):1602-1607 (May 1981).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	